Detalles de la búsqueda
1.
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
N Engl J Med
; 377(14): 1319-1330, 2017 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28844192
2.
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Lancet
; 391(10117): 219-229, 2018 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29132880
3.
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
Am Heart J
; 199: 83-91, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29754671
4.
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
Am Heart J
; 178: 176-84, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27502866
5.
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
Catheter Cardiovasc Interv
; 88(2): 163-73, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26698636
6.
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
N Engl J Med
; 366(1): 20-33, 2012 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22077816
7.
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
Am Heart J
; 168(4): 588-96, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25262270
8.
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Am Heart J
; 168(6): 869-77.e1, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25458650
9.
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
Eur Heart J
; 34(23): 1723-31, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23530022
10.
Clinical Trial Educator program - a novel approach to accelerate enrollment in a phase III International Acute Coronary Syndrome Trial.
Clin Trials
; 9(3): 358-66, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22426648
11.
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.
Can J Cardiol
; 33(8): 1027-1035, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28754388
12.
Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock.
Circulation
; 108(8): 951-7, 2003 Aug 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-12912817
13.
Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one.
Heart Rhythm
; 2(6): 569-74, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-15922261
14.
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Am J Cardiol
; 115(10): 1325-32, 2015 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25776457
15.
The association between white blood cell count and acute myocardial infarction in-hospital mortality: findings from the National Registry of Myocardial Infarction.
Acad Emerg Med
; 11(10): 1049-60, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15466147
16.
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
Am J Cardiol
; 114(5): 665-73, 2014 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25129064
17.
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.
Eur Heart J Acute Cardiovasc Care
; 3(3): 246-56, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24627331
18.
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
Am J Cardiol
; 113(6): 936-44, 2014 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24444781
19.
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
J Am Coll Cardiol
; 63(11): 1048-57, 2014 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-24211500
20.
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Thromb Haemost
; 111(5): 883-91, 2014 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24402559